Skip to content Skip to footer
Subscribe Now
THOUGHTSPOT

CEAS Collective: Bridging Biotech Innovation and Consumer Wellness Through Direct-to-Patient Delivery 

Biotech innovation is rapidly transforming the boundaries of modern wellness, and CEAS  Collective stands at the forefront of this shift. By integrating advanced product  development with a direct-to-patient delivery model, CEAS Collective bridges the gap  between next-generation health solutions and consumer-centric care. Their approach  sets a new benchmark for accessible, holistic wellness, offering patients seamless  access to science-driven products…
May 11, 2026

Read more

VIEWPOINTS

Ending Prescription Ping-Pong in Specialty Care: Colin Banas, CMO, Timely By DrFirst Shares His Vision  

Shots:  Specialty medication access remains challenged by high costs, fragmented workflows, complex prior authorization requirements, and limited transparency, leading to delays, prescription drop-offs, and suboptimal patient outcomes.  DrFirst is addressing these gaps through AI-powered, workflow-integrated solutions that enable real-time benefits verification, targeted prior authorization automation, and smarter pharmacy routing, shifting care from reactive problem-solving to proactive, frictionless prescribing.  PharmaShots welcomes…
May 4, 2026

Read more

VIEWPOINTS

From Denials to Decisions: Dr. Wael Khouli of Authsnap on AI-Powered Healthcare Appeals 

Shots:  Did you know that nearly 15–20% of healthcare claims in the U.S. are denied on first submission, creating billions of dollars in administrative costs and forcing providers into complex, time-consuming appeals processes that strain revenue cycles, clinical staff, and patient care continuity?    Authsnap is an AI healthcare technology company helps providers manage insurance denials and…
March 16, 2026

Read more

INSIGHTS+

Key Biosimilars Events of January 2026   

Shots:  Global biosimilar activity accelerated across ophthalmology, oncology, immunology, and diabetes, with new or advancing alternatives to Lucentis, Eylea, Stelara, Lantus, Avastin, Opdivo, and Neulasta, expanding patient access across Europe, the US, India, Canada, Ghana, and MENA  Regulatory and commercialization momentum remained strong, marked by FDA, EC, Health Canada, and Ghana FDA milestones, alongside Samsung Bioepis’…
February 3, 2026

Read more

VIEWPOINTS

Tariffs, Compliance, and the Future of Drug Pricing: A Conversation with Jesse Mendelsohn from Model N 

Shots:    U.S. tariff shifts are forcing pharma manufacturers to accelerate reshoring, reduce duty exposure, and stabilize pricing, fueling renewed investment in onshore final manufacturing, Most Favored Nation pricing strategies, and selective direct-to-consumer pilots to secure tariff relief amid policy volatility  As pricing, reimbursement, market access, and trade regulations evolve, companies are prioritizing late-stage, lower-risk…
November 24, 2025

Read more